Evidence map›Paper›PMID 38076783›Full record

ArticleInternational journal of hematology-oncology and stem cell research2023

Myeloid Sarcoma: Case Series with Unusual Locations.

Akram Abedi, Nasrin Namdari, Ahmad Monabati, Akbar Safaei, Parvin Rajabi, Maral Mokhtari

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology-oncology and stem cell research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Akram AbediDepartment of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Nasrin NamdariDepartment of Hematology and Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Ahmad MonabatiDepartment of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Akbar SafaeiDepartment of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Parvin RajabiDepartment of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Maral MokhtariDepartment of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz University of Medical Sciences · IRIsfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid sarcoma (MS) or chloroma is a localized mass composed of blastic cells of granulocytic lineage. It is a subtype of acute myeloid leukemia and usually presents as a complication of acute myeloid leukemia, myeloid dysplastic syndrome, or myeloproliferative disorder. MS occurs in 2.5-9.1% of patients with AML, precedes the clinical disease, coincidence with the onset or at relapse and in rare conditions, it can occur with no evidence of hematologic disorders. Here, we presented seven cases of MS in unusual locations or with rare presentations at presentation or relapse. We concluded that MS should be considered in the differential diagnosis of any high-grade tumor, especially in a patient with previous history of any myeloid neoplasm.

Indexed as

Acute leukemiaNon-leukemic myeloid sarcoma

Identifiers

PMID38076783
PMCPMC10700098
OpenAlexW4387857846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.